OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Trinity Biotech's OCF Yield % or its related term are showing as below:
FRA:TRB0'
s OCF Yield % Range Over the Past 10 Years
Min: -162.3 Med: 6.88 Max: 71.94
Current: -83.67
During the past 13 years, the highest OCF Yield % of Trinity Biotech was 71.94%. The lowest was -162.30%. And the median was 6.88%.
FRA:TRB0's OCF Yield % is ranked worse than 94.6% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.76
vs FRA:TRB0: -83.67
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Trinity Biotech OCF Yield % Related Terms
Trinity Biotech OCF Yield % Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TRB0 vs PMI, NXL, CSDX: OCF Yield % Comparison
For the Medical Devices subindustry, Trinity Biotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (FRA:TRB0) has a OCF Yield % of -83.67 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #806 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 94.6%.
Is Trinity Biotech's OCF Yield % too high?
Trinity Biotech's current OCF Yield % is -83.67. Based on the distribution chart, Trinity Biotech ranks #806 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's OCF Yield % compare to PMI and NXL?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #806 out of 852 companies for OCF Yield %. This places Trinity Biotech in the lower half of its industry. The industry median OCF Yield % is 1.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.76, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current OCF Yield % is -83.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Trinity Biotech (FRA:TRB0) has a current OCF Yield % of -83.67. The stock's GF Value™ is €4.42, compared to a current price of €2.12 — trading 52% below its estimated fair value. The current OCF Yield % is -83.67. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Trinity Biotech (FRA:TRB0), the current OCF Yield % is -83.67 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (FRA:TRB0) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of €2.12 is trading 52% below its estimated GF Value™ of €4.42.
Key valuation signals for FRA:TRB0:
OCF Yield %: -83.67
GF Value™: €4.42 vs. price of €2.12 (52% below fair value)
No single metric tells the full story. See the FRA:TRB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score
Get the complete analysis for FRA:TRB0
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TRB0 has been successfully added to your 
